In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
Dr. Elizabeth K. Lee
Advertisement
Articles by Dr. Elizabeth K. Lee
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
3 ESMO 2026 Results in Endometrial and Breast Cancer to Know
4
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
5